LadRx Corporation is dedicated to advancing biopharmaceutical innovations aimed at addressing significant unmet medical needs. The company focuses on the discovery and development of new therapeutics, which suggests a commitment to research and innovation in the biopharmaceutical sector. Their efforts are likely directed towards creating effective treatments for conditions that currently lack adequate therapeutic options, highlighting their mission to improve patient outcomes.

In their latest updates, LadRx has been involved in strategic partnerships and financial transactions to support their research initiatives. For instance, they recently completed a non-dilutive financing transaction with XOMA Corporation, which indicates a proactive approach to securing funding for their projects. Additionally, the termination of the Aldoxorubicin license with ImmunityBio reflects their strategic decision-making in managing their product pipeline and collaborations, ensuring that their focus remains on the most promising therapeutic developments.

United States

Name changed from CytRx (Ticker: CYTR) to LadRx (Ticker: LADX) on 10/5/22

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company’s advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Digestive System Diseases

Genetic Diseases

Metabolic Diseases

Musculoskeletal Diseases

Nervous System Diseases

LadRx Corporation

Niemann Pick Disease Type C

Arimoclomol is an investigational drug candidate that amplifies the production of heat-shock proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally, crosses the blood brain barrier, and has been studied in seven Phase 1, four Phase 2 and one pivotal Phase 2/3 clinical trial. Arimoclomol is in clinical development at Orphazyme for the treatment of NPC, Gaucher disease, IBM and ALS. Arimoclomol has received orphan drug designation for NPC, IBM and ALS in the US and EU, as well as fast-track designation from the US Food and Drug Administration (FDA) for NPC, IBM and ALS. In addition, arimoclomol has received breakthrough therapy designation and rare-pediatric disease designation from the FDA for NPC.
<a href="https://www.cytrx.com/wp-content/uploads/2021/04/CytRx-Notes-Orphazymes-Announcement-of-Topline-Results-from-Trial-for-Arimoclomol-in-the-Treatment-of-Inclusion-Body-Myositis.pdf">Source</a>

Arimoclomol

Pancreatic cancer

Aldoxorubicin is a rationally-engineered cytotoxic which delivers &nbsp;well-established anti-cancer agent, doxorubicin, into the tumor. &nbsp;Currently in late-stage clinical trials, aldoxorubicin appears to &nbsp;overcome the key limitations of doxorubicin, including cumulative dose &nbsp;restrictions. Aldoxorubicin utilizes an acid-sensitive linker that &nbsp;selectively binds to albumin, which may allow the cytotoxic payload to &nbsp;preferentially accumulate in the tumor and potentially spare the &nbsp;surrounding healthy tissue. This mechanism leverages the tumor's low pH &nbsp;environment, and accompanying dependency upon circulating albumin to &nbsp;fuel growth, to enable the delivery of multifold times the standard &nbsp;dosing of doxorubicin. In July 2017, CytRx out-licensed the worldwide &nbsp;rights to aldoxorubicin to NantCell, Inc. (now called ImmunityBio, &nbsp;Inc.).
<a href="https://www.cytrx.com/aldoxorubicin/">Source</a>

LadRx Corporation

Company Details